Heidelberg Pharma AG (HPHA.DE)
EUR 2.38
(-0.42%)
EUR 2.38
(-0.42%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.44 EUR | 16.98% |
| 2022 | -0.53 EUR | 35.37% |
| 2021 | -0.82 EUR | -34.43% |
| 2020 | -0.61 EUR | -69.44% |
| 2019 | -0.36 EUR | 12.2% |
| 2018 | -0.41 EUR | 46.05% |
| 2017 | -0.76 EUR | -43.4% |
| 2016 | -0.53 EUR | 29.33% |
| 2015 | -0.75 EUR | -13.64% |
| 2014 | -0.66 EUR | -8.2% |
| 2013 | -0.61 EUR | 55.47% |
| 2012 | -1.37 EUR | 46.06% |
| 2011 | -2.54 EUR | 50.49% |
| 2010 | -5.13 EUR | -44.51% |
| 2009 | -3.55 EUR | 44.18% |
| 2008 | -6.36 EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.10 EUR | 0.31% |
| 2024 Q2 | -0.09 EUR | 7.16% |
| 2024 Q3 | -0.12 EUR | -34.08% |
| 2023 Q2 | -0.20 EUR | -42.86% |
| 2023 Q1 | -0.14 EUR | 17.65% |
| 2023 Q3 | 0.00 EUR | 101.2% |
| 2023 Q4 | -0.10 EUR | -4129.17% |
| 2023 FY | - EUR | 16.98% |
| 2022 Q4 | -0.17 EUR | -437.97% |
| 2022 Q1 | -0.22 EUR | 0.0% |
| 2022 Q2 | -0.04 EUR | 81.95% |
| 2022 Q3 | -0.03 EUR | 20.4% |
| 2022 FY | - EUR | 35.37% |
| 2021 Q1 | -0.20 EUR | 4.76% |
| 2021 Q3 | -0.18 EUR | 18.18% |
| 2021 Q4 | -0.22 EUR | -22.22% |
| 2021 Q2 | -0.22 EUR | -10.0% |
| 2021 FY | - EUR | -34.43% |
| 2020 Q1 | -0.16 EUR | 0.0% |
| 2020 FY | - EUR | -69.44% |
| 2020 Q2 | -0.17 EUR | -6.25% |
| 2020 Q3 | -0.11 EUR | 35.29% |
| 2020 Q4 | -0.21 EUR | -90.91% |
| 2019 FY | - EUR | 12.2% |
| 2019 Q1 | -0.11 EUR | 31.25% |
| 2019 Q2 | -0.04 EUR | 60.09% |
| 2019 Q3 | -0.05 EUR | -6.15% |
| 2019 Q4 | -0.16 EUR | -243.35% |
| 2018 Q1 | -0.09 EUR | 25.0% |
| 2018 Q2 | -0.08 EUR | 9.44% |
| 2018 FY | - EUR | 46.05% |
| 2018 Q4 | -0.16 EUR | -68.95% |
| 2018 Q3 | -0.09 EUR | -16.2% |
| 2017 FY | - EUR | -43.4% |
| 2017 Q3 | -0.12 EUR | 29.41% |
| 2017 Q4 | -0.12 EUR | 0.0% |
| 2017 Q2 | -0.17 EUR | -13.33% |
| 2017 Q1 | -0.15 EUR | -88.92% |
| 2016 Q2 | -0.11 EUR | -10.0% |
| 2016 Q3 | -0.06 EUR | 44.73% |
| 2016 FY | - EUR | 29.33% |
| 2016 Q1 | -0.10 EUR | 69.7% |
| 2016 Q4 | -0.08 EUR | -30.59% |
| 2015 Q2 | -0.09 EUR | 32.21% |
| 2015 FY | - EUR | -13.64% |
| 2015 Q1 | -0.14 EUR | 70.21% |
| 2015 Q4 | -0.33 EUR | -94.12% |
| 2015 Q3 | -0.17 EUR | -79.14% |
| 2014 FY | - EUR | -8.2% |
| 2014 Q4 | -0.47 EUR | -188.68% |
| 2014 Q3 | 0.53 EUR | 411.76% |
| 2014 Q2 | -0.17 EUR | 51.43% |
| 2014 Q1 | -0.35 EUR | -169.23% |
| 2013 Q4 | -0.13 EUR | -158.96% |
| 2013 FY | - EUR | 55.47% |
| 2013 Q1 | -0.24 EUR | 17.24% |
| 2013 Q2 | -0.19 EUR | 20.83% |
| 2013 Q3 | -0.05 EUR | 73.58% |
| 2012 FY | - EUR | 46.06% |
| 2012 Q1 | -0.43 EUR | -1662.3% |
| 2012 Q2 | -0.46 EUR | -6.98% |
| 2012 Q3 | -0.27 EUR | 41.3% |
| 2012 Q4 | -0.29 EUR | -7.41% |
| 2011 Q1 | -1.22 EUR | -480.95% |
| 2011 Q3 | -0.09 EUR | 42.94% |
| 2011 Q2 | -0.16 EUR | 86.89% |
| 2011 FY | - EUR | 50.49% |
| 2011 Q4 | -0.02 EUR | 73.27% |
| 2010 FY | - EUR | -44.51% |
| 2010 Q2 | -0.22 EUR | 82.54% |
| 2010 Q3 | -1.26 EUR | -472.73% |
| 2010 Q1 | -1.26 EUR | -2053.85% |
| 2010 Q4 | -0.21 EUR | 83.33% |
| 2009 Q4 | -0.06 EUR | 65.59% |
| 2009 Q3 | -0.17 EUR | -6.25% |
| 2009 Q2 | -0.16 EUR | 90.96% |
| 2009 Q1 | -1.77 EUR | 0.0% |
| 2009 FY | - EUR | 44.18% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| BioNTech SE | 3.87 EUR | 111.37% |
| CureVac N.V. | -1.18 EUR | 62.712% |
| Biotest Aktiengesellschaft | 3.21 EUR | 113.707% |
| Biotest Aktiengesellschaft | 3.21 EUR | 113.707% |
| BRAIN Biotech AG | -0.38 EUR | -15.789% |
| Formycon AG | 4.76 EUR | 109.244% |
| Medigene AG | -0.66 EUR | 33.333% |